Image Source: AsiaOne
Rhizen Pharmaceuticals S.A. Announces Publication of Clinical Data from the Phase I/Ib study of Tenalisib (RP6530) in Patients with Relapsed/Refractory T-Cell Lymphoma (TCL) GlobeNewswire September 24, 2020 La Chaux-de-Fonds, Switzerland, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers. --- Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell Lymphoma patients (PTCL and CTCL) The results include safety and efficacy information from 58 heavily pre-treated patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma treated with single-agent Tenalisib. Tenalisib was well tolerated with favorable safety profile compared to prior generation dual PI3K δ/γ inhibitors.